Abstract
Artificial intelligence (AI)-based tools are widely employed, but their use for diagnosis and prognosis of neurological disorders is still evolving. We capitalise on a large-scale, cross-sectional structural MRI dataset of 814 people with epilepsy. We use a recently developed machine-learning algorithm, Subtype and Stage Inference (SuStaIn), to develop a novel data-driven disease taxonomy based on distinct patterns of spatiotemporal progression of brain atrophy. We identify two subtypes common to focal and idiopathic generalised epilepsies, characterised by neocortical-driven or basal ganglia-driven progression, and a third subtype, only detected in focal epilepsies, characterised by hippocampus-driven progression. We corroborate external validity via an independent cohort of 254 people and decode associations between progression subtypes and clinical measures of epilepsy severity. Our findings suggest fundamental processes underlying the progression of epilepsy-related brain atrophy. We deliver a novel MRI- and AI-guided epilepsy taxonomy, which could be used for individualised prognostics and targeted therapeutics.
Competing Interest Statement
JWS reports personal fees as a speaker or consultant from Arvelle, Eisai, GW Pharmaceuticals, UCB Pharma, and Zogenix. The other authors report no conflicting interests in relation to this submission.
Funding Statement
We thank the people with epilepsy and the controls for participation, and Drs Christian Vollmar and Maria Centeno for recruiting part of the controls. This work was supported by the Epilepsy Society, Chalfont St Peter, UK and was carried out at the National Institute for Health Research University College London Hospitals Biomedical Research Centre, which receives a proportion of funding from the UK Department of Health's Research Centres funding scheme. FX is supported by a Newton International Fellowship of the Academy of Medical Sciences and the Newton Fund (NIF\R5\264) and acknowledges support from the National Natural Science Foundation of China (82001369). LC acknowledges support from Brain Research UK (award n. 14181). BW acknowledges support from the MRC (MR/T005335/1). ALY is supported by an MRC Skills Development Fellowship (MR/T027800/1). Part of participant recruitment was funded through Wellcome Trust awards (project grants 083148 and 079474) to JD and MK. JD acknowledges support from the NIHR and Wellcome Trust (218380). GPW was funded by the MRC (G0802012, MR/M00841X/1). DCA acknowledges support by the Wellcome Trust (221915) for work in this area. BK is supported by the National Institute for Health Research Biomedical Research Centre at UCLH and UCL. JWS receives support from the Dr Marvin Weil Epilepsy Research Fund and the Christelijke Verenigingvoor de Verpleging van Lijdersaan Epilepsie, Netherlands. The authors also acknowledge the facilities and scientific and technical assistance of the National Imaging Facility, a National Collaborative Research Infrastructure Strategy (NCRIS) capability, at the Centre for Microscopy, Characterisation, and Analysis, the University of Western Australia.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was pursued under a protocol approved by the UCL and University College London Hospital Joint Research Ethics Committee (20/LO/0149) and involved the analysis of previously acquired clinical data posing no risk to patients and did not require individual patient consent. The recruitment of healthy controls was approved by the UCL and University College London Hospital Joint Research Ethics Committee as part of previous studies. Written informed consent was obtained from healthy control participants per the Declaration of Helsinki standards. Participant recruitment in relation to validation cohort data was approved by the West China Hospital Clinical Trials and Biomedical Ethics Committee of Sichuan University. All participants from Sichuan University gave written informed consent by the standards of the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of interest: JWS reports personal fees as a speaker or consultant from Arvelle, Eisai, GW Pharmaceuticals, UCB Pharma, and Zogenix. The other authors report no conflicts of interest in relation to this submission.
Data Availability
Anonymized statistical data to reproduce the main findings are available from the corresponding author upon reasonable request from any qualified investigator. Other data are not available due to their containing information that could compromise the privacy of research participants.